Progress in Gene Therapy for Chronic Heart Failure
DOI:
https://doi.org/10.1532/hsf.1865Keywords:
molecular cardiac surgery with recirculating delivery, gene delivery methods, cardiac gene therapy, chronic heart failure,Abstract
Chronic heart failure (CHF) is still the leading cause of morbidity and mortality worldwide, and carries with it large economic and social burdens. Although steady and substantial progress has been made in reducing mortality from heart failure using conventional treatments, novel pharmacologic and surgical interventions have not been effective in extending five year survival rates. Therefore, it is necessary to explore new therapies. Gene therapy was introduced in 1970s with the development of recombinant DNA technology. Due to recent progress in the understanding of myocardial metabolism and application of vector based gene transfer strategies in animal models and initial clinical trials, gene therapy possibly affords an ideal treatment alternative for CHF. In last 2 decades, much research has been done on gene therapy, using various genes, signal transduction passages and delivery methods to treat advanced heart failure. Current research in ischemic heart disease (IHD) mainly focuses on stimulating angiogenesis, modifying the coronary vascular environment, and improving the vascular endothelial function with localized gene coated catheters and stents. Compared with standard ischemic heart disease treatment, the main goal of gene therapy for CHF is to inhibit apoptosis, reduce the undesirable remodeling and increase contractility through the most efficient cardiomyocyte transfection [Katz 2012a]. In this paper, we review various gene transfer technologies in ischemic heart disease and heart failure models, and discuss the advantages and disadvantages of these strategies in vector-mediated cardiac gene delivery, with the main focus on the high efficiency approach of a molecular cardiac surgery delivery system.
References
Barr E, Carroll J, Kalynych AM, et al. 1994. Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus. Gene Ther 1:51-8.
Boekstegers P, Kupatt C. 2004. Current concepts and applications of coronary venous retroinfusion. Basic Res Cardiol 99:373-81.
Boekstegers P, von Degenfeld G, Giehrl W, et al. 2000. Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins. Gene Ther 7:232-40.
Bridges CR. 2009. ‘Recirculating cardiac delivery’ method of gene delivery should be called ‘non-recirculating’ method. Gene Ther 16:939-40.
Byrne MJ, Power JM, Preovolos A, et al. 2008. Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Ther 15:1550-7.
Edelberg JM, Huang DT, Josephson ME, Rosenberg RD. 2001. Molecular enhancement of porcine cardiac chronotropy. Heart 86:559-62.
Edelstein ML, Abedi MR, Wixon J. 2007. Gene therapy clinical trials worldwide to 2007--an update. J Gene Med 9:833-42.
Emani SM, Shah AS, Bowman MK, et al. 2003. Catheter-based intracoronary myocardial adenoviral gene delivery: importance of intraluminal seal and infusion flow rate. Mol Ther 8:306-13.
Fargnoli AS, Katz MG, Bridges CR. 2017. A Needleless Liquid Jet Injection Delivery Approach for Cardiac Gene Therapy. Methods Mol Biol 1521:219-226.
Fargnoli AS, Katz MG, Williams RD, Margulies KB, Bridges CR. 2014. A needleless liquid jet injection delivery method for cardiac gene therapy: a comparative evaluation versus standard routes of delivery reveals enhanced therapeutic retention and cardiac specific gene expression. J Cardiovasc Transl Res 7:756-67.
Fargnoli AS, Katz MG, Yarnall C, et al. 2011. A pharmacokinetic analysis of molecular cardiac surgery with recirculation mediated delivery of betaARKct gene therapy: developing a quantitative definition of the therapeutic window. J Card Fail 17:691-9.
Fishbein I, Chorny M, Levy RJ. 2010. Site-specific gene therapy for cardiovascular disease. Curr Opin Drug Discov Devel 13:203-13.
French BA, Mazur W, Geske RS, Bolli R. 1994. Direct in vivo gene transfer into porcine myocardium using replication-deficient adenoviral vectors. Circulation 90:2414-24.
Fromes Y, Salmon A, Wang X, et al. 1999. Gene delivery to the myocardium by intrapericardial injection. Gene Ther 6:683-8.
Gaffney MM, Hynes SO, Barry F, O’Brien T. 2007. Cardiovascular gene therapy: current status and therapeutic potential. Br J Pharmacol 152:175-88.
Giacca M, Zacchigna S. 2012. Virus-mediated gene delivery for human gene therapy. J Control Release 161:377-88.
Giordano FJ. 2003. Retrograde coronary perfusion: a superior route to deliver therapeutics to the heart? J Am Coll Cardiol 42:1129-31.
Guzman RJ, Lemarchand P, Crystal RG, Epstein SE, Finkel T. 1993. Efficient gene transfer into myocardium by direct injection of adenovirus vectors. Circ Res 73:1202-7.
Hajjar RJ, Schmidt U, Matsui T, et al. 1998. Modulation of ventricular function through gene transfer in vivo. Proc Natl Acad Sci U S A 95:5251-6.
Hayase M, Del Monte F, Kawase Y, et al. 2005. Catheter-based antegrade intracoronary viral gene delivery with coronary venous blockade. Am J Physiol Heart Circ Physiol 288:H2995-3000.
Hiltunen MO, Turunen MP, Turunen AM, et al. 2000. Biodistribution of adenoviral vector to nontarget tissues after local in vivo gene transfer to arterial wall using intravascular and periadventitial gene delivery methods. Faseb j 14:2230-6.
Hoshino K, Kimura T, De Grand AM, et al. 2006. Three catheter-based strategies for cardiac delivery of therapeutic gelatin microspheres. Gene Ther 13:1320-7.
Hou J, Kang YJ. 2012. Regression of pathological cardiac hypertrophy: signaling pathways and therapeutic targets. Pharmacol Ther 135:337-54.
Kaplitt MG, Xiao X, Samulski RJ, et al. 1996. Long-term gene transfer in porcine myocardium after coronary infusion of an adeno-associated virus vector. Ann Thorac Surg 62:1669-76.
Katz MG, Fargnoli AS, Bridges CR. 2013a. Myocardial gene transfer: routes and devices for regulation of transgene expression by modulation of cellular permeability. Hum Gene Ther 24:375-92.
Katz MG, Fargnoli AS, Kendle AP, Bridges CR. 2017. Molecular Cardiac Surgery with Recirculating Delivery (MCARD): Procedure and Vector Transfer. Methods Mol Biol 1521:271-289.
Katz MG, Fargnoli AS, Pritchette LA, Bridges CR. 2012a. Gene delivery technologies for cardiac applications. Gene Ther 19:659-69.
Katz MG, Fargnoli AS, Swain JD, et al. 2012b. AAV6-betaARKct gene delivery mediated by molecular cardiac surgery with recirculating delivery (MCARD) in sheep results in robust gene expression and increased adrenergic reserve. J Thorac Cardiovasc Surg 143:720-726.e3.
Katz MG, Fargnoli AS, Williams RD, Bridges CR. 2013b. Gene therapy delivery systems for enhancing viral and nonviral vectors for cardiac diseases: current concepts and future applications. Hum Gene Ther 24:914-27.
Katz MG, Fargnoli AS, Williams RD, Bridges CR. 2014a. The road ahead: working towards effective clinical translation of myocardial gene therapies. Ther Deliv 5:39-51.
Katz MG, Fargnoli AS, Williams RD, Bridges CR. 2014b. Surgical methods for cardiac gene transfer. Future Cardiol 10:323-6.
Katz MG, Fargnoli AS, Williams RD, et al. 2014c. Safety and efficacy of high-dose adeno-associated virus 9 encoding sarcoplasmic reticulum Ca(2+) adenosine triphosphatase delivered by molecular cardiac surgery with recirculating delivery in ovine ischemic cardiomyopathy. J Thorac Cardiovasc Surg 148:1065-72, 1073e1-2; discussion1072-3.
Katz MG, Swain JD, Fargnoli AS, Bridges CR. 2010. Gene therapy during cardiac surgery: role of surgical technique to minimize collateral organ gene expression. Interact Cardiovasc Thorac Surg 11:727-31.
Katz MG, Swain JD, Tomasulo CE, et al. 2011. Current strategies for myocardial gene delivery. J Mol Cell Cardiol 50:766-76.
Kawase Y, Ladage D, Hajjar RJ. 2011. Rescuing the failing heart by targeted gene transfer. J Am Coll Cardiol 57:1169-80.
Kawase Y, Ly HQ, Prunier F, et al. 2008. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol 51:112-9.
Kaye DM, Preovolos A, Marshall T, et al. 2007. Percutaneous cardiac recirculation-mediated gene transfer of an inhibitory phospholamban peptide reverses advanced heart failure in large animals. J Am Coll Cardiol 50:253-60.
Kornowski R, Fuchs S, Leon MB, Epstein SE. 2000. Delivery strategies to achieve therapeutic myocardial angiogenesis. Circulation 101:454-8.
Kupatt C, Wichels R, Deiss M, et al. 2002. Retroinfusion of NFkappaB decoy oligonucleotide extends cardioprotection achieved by CD18 inhibition in a preclinical study of myocardial ischemia and retroinfusion in pigs. Gene Ther 9:518-26.
Ladage D, Ishikawa K, Tilemann L, Muller-Ehmsen J, Kawase Y. 2012. Percutaneous methods of vector delivery in preclinical models. Gene Ther 19:637-41.
Lamping KG, Rios CD, Chun JA, et al. 1997. Intrapericardial administration of adenovirus for gene transfer. Am J Physiol 272:H310-7.
Lassaletta AD, Chu LM, Sellke FW. 2011. Therapeutic neovascularization for coronary disease: current state and future prospects. Basic Res Cardiol 106:897-909.
Lazarous DF, Shou M, Stiber JA, et al. 1997. Pharmacodynamics of basic fibroblast growth factor: route of administration determines myocardial and systemic distribution. Cardiovasc Res 36:78-85.
Lin H, Parmacek MS, Morle G, Bolling S, Leiden JM. 1990. Expression of recombinant genes in myocardium in vivo after direct injection of DNA. Circulation 82:2217-21.
McMahon JM, Wells DJ. 2004. Electroporation for gene transfer to skeletal muscles: current status. BioDrugs 18:155-65.
Melo LG, Pachori AS, Gnecchi M, Dzau VJ. 2005. Genetic therapies for cardiovascular diseases. Trends Mol Med 11:240-50.
Packer M, Coats AJ, Fowler MB, et al. 2001. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-8.
Quarck R, Holvoet P. 2004. Gene therapy approaches for cardiovascular diseases. Curr Gene Ther 4:207-23.
Raake P, von Degenfeld G, Hinkel R, et al. 2004. Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins: comparison with surgical and percutaneous intramyocardial gene delivery. J Am Coll Cardiol 44:1124-9.
Raake PW, Hinkel R, Muller S, et al. 2008. Cardio-specific long-term gene expression in a porcine model after selective pressure-regulated retroinfusion of adeno-associated viral (AAV) vectors. Gene Ther 15:12-7.
Rengo G, Lymperopoulos A, Leosco D, Koch WJ. 2011. GRK2 as a novel gene therapy target in heart failure. J Mol Cell Cardiol 50:785-92.
Rengo G, Lymperopoulos A, Zincarelli C, et al. 2009. Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation 119:89-98.
Roques C, Salmon A, Fiszman MY, Fattal E, Fromes Y. 2007. Intrapericardial administration of novel DNA formulations based on thermosensitive Poloxamer 407 gel. Int J Pharm 331:220-3.
Rose EA, Gelijns AC, Moskowitz AJ, et al. 2001. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 345:1435-43.
Schwarz ER, Speakman MT, Patterson M, et al. 2000. Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat--angiogenesis and angioma formation. J Am Coll Cardiol 35:1323-30.
Scott NA, Cipolla GD, Ross CE, et al. 1996. Identification of a potential role for the adventitia in vascular lesion formation after balloon overstretch injury of porcine coronary arteries. Circulation 93:2178-87.
Sharif F, Daly K, Crowley J, O’Brien T. 2004. Current status of catheter- and stent-based gene therapy. Cardiovasc Res 64:208-16.
Sharif F, Hynes SO, McMahon J, et al. 2006. Gene-eluting stents: comparison of adenoviral and adeno- associated viral gene delivery to the blood vessel wall in vivo. Hum Gene Ther 17:741-50.
von Degenfeld G, Raake P, Kupatt C, et al. 2003. Selective pressure-regulated retroinfusion of fibroblast growth factor-2 into the coronary vein enhances regional myocardial blood flow and function in pigs with chronic myocardial ischemia. J Am Coll Cardiol 42:1120-8.
Wever-Pinzon O, Stehlik J, Kfoury AG, et al. 2012. Ventricular assist devices: pharmacological aspects of a mechanical therapy. Pharmacol Ther 134:189-99.
White JD, Thesier DM, Swain JB, et al. 2011. Myocardial gene delivery using molecular cardiac surgery with recombinant adeno-associated virus vectors in vivo. Gene Ther 18:546-52.
Wright MJ, Wightman LM, Latchman DS, Marber MS. 2001. In vivo myocardial gene transfer: optimization and evaluation of intracoronary gene delivery in vivo. Gene Ther 8:1833-9.
